Erratum: The impact of one or two missed doses on the duration of action of combined perindopril and indapamide (Journal of Human Hypertension (2007) vol. 21 (86-93) doi:10.1038/sj.jhh.1002107);The impact of one or two missed doses on the duration of action of combined perindopril and indapamide

Journal of Human Hypertension

Volumn 21, Issue 1, 2007, Pages 86-93

  Myers, M G ^a   Leenen, F H H ^b  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

INDAPAMIDE; INDAPAMINE PLUS PERINDOPRIL; PERINDOPRIL; PLACEBO;

ADULT; AGED; ANTIHYPERTENSIVE ACTIVITY; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG FATALITY; FEMALE; HUMAN; HYPERTENSION; HYPOKALEMIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHYSICAL DISEASE; POTASSIUM BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; URIC ACID BLOOD LEVEL;

EID: 33845536973     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/sj.jhh.1002307     Document Type: Erratum

References (28)

1. Mancia G, Grassi G. Rationale for the use of a fixed combination in the treatment of hypertension. Eur Heart J 1999; 1(Suppl): L14-L19.
2. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981-2997.
3. Hansson L, Zanchetti A, Carruthers SG, Dahlöf B, Elmfeldt D, Julius S et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351: 1755-1762.
4. Brown MJ, Palmer CR, Castaigne A, deLeeuw PW, Mancia G, Rosenthal T et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000; 356: 366-372.
5. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet 2002; 359: 995-1003.
6. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. JAMA 2003; 289: 2560-2572.
7. Guidelines Committee. 2003 European Society of Hypertension - European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011-1053.
8. Khan NA, McAlister FA, Lewanczuk RZ, Touyz RM, Padwal R, Rabkin SW et al. The 2005 Canadian Hypertension Education Program recommendations for the management of hypertension: Part II - therapy. Can J Cardiol 2005; 21(8): 657-672.
9. Safar M, Zanchetti A, Sever PS, Anlauf M, Calvo Gomez C, De Leeuw PW et al. Perindopril and indapamide as a combination therapy in the treatment of mild to moderate hypertension. A double-blind, randomized, placebo-controlled European multi-centre study. Eur Heart J 1994; 15(Suppl): 195.
10. Myers MG, Asmar R, Leenen FH, Safar M. Fixed low-dose combination therapy in hypertension - a dose response study of perindopril and indapamide. J Hypertens 2000; 18: 317-325.
11. Myers MG, Leenen FHH, Tanner J. Assessment of the first line low-dose combination of perindopril 2 mg+indapamide 0.625mg using the missed dose technique. J Hypertension 2003; 21: S178.
12. Myers MG, Leenen FHH. Persistence of the antihypertensive effect of low-dose combination therapy in mild hypertension. Blood Pressure (in press).
13. Sackett DL. The hypertensive patient: 5. Compliance with therapy. Can Med Assoc J 1979; 121: 259-261.
14. Chrysant SG, McDonald RH, Wright JT, Barden PL, Weiss RJ, for the Perindopril Study Group. Perindopril as monotherapy in hypertension: A multicenter comparison of two dosing regimens. Clin Pharmacol Ther 1993; 53: 479-484.
15. Ménard J, Bellet M, Brunner HR. Clinical development of antihypertensive drugs: Can we perform better? In: Laragh JH, Brenner BM (eds). Hypertension: Pathophysiology, Diagnosis and Management, 1st edn. Raven Press Limited: New York, 1990, pp 2331-2350.
16. Vaur L, Dutrey-Dupagne C, Boussac J, Genes N, Bouvier d'Yvoire M, Elkik F et al. Differential effects of a missed dose of trandolapril and enalapril on blood pressure control in hypertensive patients. J Cardiovas Pharmacol 1995; 26: 127-131.
17. McCarron D, The Ramipril Multicenter Study Group. 24-Hour blood pressure profiles in hypertensive patients administered ramipril or placebo once daily: Magnitude and duration of antihypertensive effects. Clin Cardiol 1991; 14: 737-742.
18. Mansoor GA, McCabe EJ, White WB. Long-term reproducibility of ambulatory blood pressure. J Hypertens 1994; 12: 703-708.
19. Palatini P, Mormino P, Canali C, Santonastaso M, De Venuto G, Zanata G et al. Factors affecting ambulatory blood pressure reproducibility. Results of the HARVEST trial. Hypertension 1994; 23: 211-216.
20. Leenen FHH, Myers MG, Joyner CD, Toal CB. Differential effects of once-daily antihypertensive drugs on blood pressure, left ventricular mass and sympathetic activity: Nifedipine-GITS versus felodipine-ER versus enalapril. Can J Cardiol 2002; 18: 1285-1293.
21. Leenen FH, Forney A, Notman G, Tanner J. Persistence of anti-hypertensive effect after 'missed doses' of calcium antagonist with long (amlodipine) vs short (diltiazem) elimination half-life. Br J Clin Pharmacol 1996; 41: 83-88.
22. Smilde JG. A comparison of amlodipine and felodipine extended release in the treatment of hypertension at steady state and after two missed doses. Curr Ther Res 1997; 58: 141-153.
23. Tan KW, Leenen FH. Persistence of anti-hypertensive effect after missed dose of perindopril. J Clin Pharmacol 1999; 48: 628-629.
24. Skoularigis J, Strugo V, Chopamba A, Setekge S, Sareli P. Low dose hydrochlorothiazide (12.5 to 25 mg daily) as monotherapy in black patients with mild to moderate hypertension. Assessment by ambulatory blood pressure monitoring. Am J Hypertens 1995; 8: 1046-1050.
25. Wiggam MI, Bell PM, Sheridan B, Walmsley A, Atkinson AB. Low dose bendrofluazide (1.25 mg) effectively lowers blood pressure over 24 h. Am J Hypertens 1999; 12: 528-531.
26. Resplandy G, Genissel P. Pharmacokinetics of perindopril in high-risk populations. J Cardiovasc Pharmacol 1991; 18(Suppl 7): S9-S18.
27. Matheson AJ, Cheer SM, Goa KL. Perindopril/indapamide 2/0.625 mg/day - a review of its place in the management of hypertension. Drugs 2001; 6: 1211-1229.
28. Bussien J-P, d'Amore TF, Perret L, Porche M, Nussberger J, Waeber B et al. Single and repeated dosing of the converting enzyme inhibitor perindopril to normal subjects. Clin Pharmacol Ther 1986; 39: 554-558.